• Although I’ve been a part of a number of successful drug launches at Incyte Corporation, DuPont and Merck, I’ve seen an even larger number of program failures. The Gliknik team is taking on immense challenges as it seeks to discover and develop drugs for cancers and immune disorders, and I believe they’ve got what it takes to succeed.

    – Paul Friedman, M.D., Gliknik Board Member

  • For me, it’s a matter of pride that important drugs from my labs have made it to the market and are being used so widely in combination therapy for HIV and more recently in Hepatitis C. I’m also proud to be on the Board of Gliknik, which I expect will generate significant new treatment options for people living with autoimmune diseases and cancers. I enjoy sharing what I have learned starting and selling several biotech companies.  

    – Raymond Schinazi, Ph.D., D.Sc., Gliknik Board Member

  • We have taken a bit of a different path than that taken by other companies – and it seems to be working. We are finding and advancing multiple drugs that may help a lot of people with cancers and autoimmune disorders.

    – David Block, Gliknik Co-Founder & CEO

  • I’m passionate about finding better treatment options for cancer patients. Before I co-invented the cancer immunomodulators now licensed to Gliknik, I was one of the inventors of using anti-PD-L1 antibodies for the treatment of cancer. By harnessing the power of the immune system, biropepimut-S, targeted against cancer protein MAGE-A3, is designed as a new approach to cancer. It has a number of built-in features that may make a difference for people living with various cancers, including of the head and neck.

    – Scott Strome, M.D., Executive Dean and Vice Chancellor, University of Tennessee Health Science Center

Biropepimut-S in phase IIb head and neck cancer trial

Biropepimut-S (GL-0817) is a highly engineered peptide immunomodulator currently in a double blind, placebo controlled clinical trial to prevent recurrence of high risk squamous cell cancer of the oral cavity. Patients with high risk SCCOC have a nearly 70% recurrence rate within 3 years despite surgery, chemoradiotherapy, and a clean CT scan.

Designed in response to previous challenges with clinical immunomodulator studies, biropepimut-S has a number of advanced features that enhance antigen presentation that are not available in any competitive product. These features and a carefully designed trial for a population with low initial tumor burden and high unmet medical need make this an important clinical trial for these patients.

Learn More About Biropepimut-S »

Pfizer Advancing GL-2045

GL-2045 is a recombinant Fc fusion protein in clinical trial designed to mimic the effects of the pooled human blood product IVIG in treating autoimmune disease. IVIG sells about $8 billion annually and is approved for use clinically in numerous autoimmune diseases. Gliknik and Pfizer entered into a licensing agreement with Pfizer responsible for ongoing clinical development of the compound.

GL-2045 is from a class of compounds invented by Gliknik called stradomersTM, which present multiple immunoglobulin Fc simultaneously to Fc receptors and ligands as a means of modulating both Fc receptor-mediated activity and complement-mediated activity to treat autoimmunity.

Learn More About GL-2045 »

Our Approach

At Gliknik, our mission is to discover and develop truly innovative biologics for people living with cancer and immune disorders. Headquartered in downtown Baltimore, Gliknik’s expertise is in modulation of the immune system to fight disease.

Our perseverance and determination to make a difference in the lives of individuals with cancer and autoimmune disease is evidenced by the assembly of a talented team of scientists, augmented by our Board members, scientific advisors and a network of worldwide scientific and medical thought leaders.

Learn More About Our Approach »